Xencor, Inc Non Peo Neo Avg Total Comp Amt
Xencor, Inc (XNCR) reported Non Peo Neo Avg Total Comp Amt of $1.39 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-27.
Financial Statements › Notes
ecd:NonPeoNeoAvgTotalCompAmt · last filed 2026-04-27
| Period end | Non Peo Neo Avg Total Comp Amt 12 month |
|---|---|
| 2025-12-31 | $1.39M DEF 14A · filed 2026-04-27 |
| 2024-12-31 | $3.14M DEF 14A · filed 2026-04-27 |
| 2023-12-31 | $3.12M DEF 14A · filed 2026-04-27 |
| 2022-12-31 | $2.44M DEF 14A · filed 2026-04-27 |
| 2021-12-31 | $2.13M DEF 14A · filed 2026-04-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |